Clinical trial NCT03502785: INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma
Official title: An Open-Label, Multi-Center Trial of INO-5401 + INO-9012 in Combination With Atezolizumab in Subjects With Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE1
PHASE2
Conditions: Urothelial Carcinoma
Lead sponsor: Inovio Pharmaceuticals
Sponsor class: INDUSTRY
First posted: 2018-04-19
Enrollment: 35
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a Phase I/IIA, open-label, multi-center trial to evaluate the safety, immunogenicity and preliminary clinical efficacy of INO-5401 + INO-9012 delivered by intramuscular (IM) injection followed by electroporation (EP), in combination with atezolizumab in participants with locally advanced unresectable or metastatic/recurrent Urothelial Carcinoma (UCa). The trial population is divided into two cohorts: Cohort A: Participants with locally advanced unresectable or metastatic/recurrent UCa, who have confirmed disease progression during or following treatment with anti-Programmed Death receptor-1/Programmed Death receptor Ligand-1 (anti-PD-1/PD-L1) therapy; Cohort B: Participants with locally advanced unresectable or metastatic/recurrent UCa, who are treatment naïve and ineligible for cisplatin-based chemotherapy. A safety run-in will be performed with up to six participants (safety analysis participants) from cohort A.


Eligibility criteria: Inclusion Criteria:

* Sign an Informed Consent Form (ICF);
* Have histologically or cytologically documented locally advanced unresectable or metastatic/recurrent urothelial carcinoma (including renal pelvis, ureters, urinary bladder, and urethra);
* For Cohort A: Subjects who have radiographically confirmed disease progression during or following treatment with an anti-PD-1/PD-L1 based therapy;
* For Cohort B: No prior chemotherapy for inoperable locally advanced or metastatic or recurrent UCa and ineligible ("unfit") for cisplatin-based chemotherapy;
* Have measurable disease, as defined by RECIST version 1.1;
* Have a performance status of 0 or 1 on Eastern Cooperative Oncology Group (ECOG) Performance Scale;
* Have life expectancy of \>/= 3 months;
* Be willing to provide a tissue sample for pre-treatment intra-tumoral assessment of proinflammatory and immunosuppressive factors;
* Have electrocardiogram (ECG) with no clinically significant findings as assessed by the investigator performed within 28 days prior to first dose;
* Demonstrate adequate hematological, renal, hepatic, and coagulation function;
* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of \< 1% per year during the treatment period and for at least 5 months after the last dose of study treatment;
* For male subjects: agreement not to father a child. Participants must be surgically sterile (e.g, vasectomy) or use contraceptive methods that result in a failure rate of \< 1% per year during the treatment period and for at least 5 months after the last dose of study treatment.

Exclusion Criteria:

* Any approved anti-cancer therapy including chemotherapy, targeted small molecule therapy or radiation therapy within 2 weeks prior to trial Day 0 as well as current participation or recipient of treatment on a clinical trial within 28 days prior to Day 0;
* Documented active or untreated central nervous system (CNS) metastases and/or carcinomatous meningitis;
* Malignancies other than UCa within 3 years prior to Day 0, with the exception of those with negligible risk of metastasis or death treated with expected curative outcome;
* Prior treatment with CD137 agonists or immune checkpoint blockade therapies;
* Treatment with systemic immunostimulatory agents;
* Treatment with systemic immunosuppressive medication;
* History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins;
* Known hypersensitivity allergy or contraindication to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the PD-1/PD-L1 inhibitor formulation;
* Active or history of autoimmune disease or immune deficiency;
* History or any evidence of interstitial lung disease;
* History of human immunodeficiency virus (HIV);
* Active hepatitis B or active hepatitis C;
* Severe infections within 4 weeks prior to enrollment;
* Received therapeutic oral or IV antibiotics within 2 weeks prior to Day 0;
* History or current evidence of any condition, therapy or laboratory abnormality that might confound the results of the trial; interfere with the subject's participation for the full duration of the trial, or is negatively impacted by EP treatment, or is not in the best interest of the subject to participate in the opinion of the treating investigator;
* Prior allogeneic stem cell or solid organ transplant;
* Uncontrolled tumor-related pain; pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures; or, hypercalcemia or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy or denosumab.

Primary outcomes:
measure: Number of Adverse Events
timeFrame: From baseline up to 90 days after last dose of study medication (up to approximately 2 years and 3 months)
measure: Antigen-Specific Cellular Immune Response
timeFrame: At baseline, Weeks 3, 6, 9, 12 and every 12 weeks thereafter up to end of study (up to approximately 2 years)
measure: Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by Investigator Review in Cohort A
timeFrame: From Baseline to disease progression or death, whichever occurs first (up to approximately 2 years)
Secondary outcomes:
measure: ORR by RECIST version 1.1 by Investigator Review in Cohort B
timeFrame: From Baseline to disease progression or death, whichever occurs first (up to approximately 2 years)
measure: ORR by Immune RECIST (iRECIST)
timeFrame: From Baseline to disease progression or death, whichever occurs first (up to approximately 2 years)
measure: Duration of Response (DoR)
timeFrame: From Baseline to disease progression or death, whichever occurs first (up to approximately 2 years)
measure: Progression Free Survival (PFS) as Assessed by RECIST version 1.1 and iRECIST
timeFrame: From Baseline to disease progression or death, whichever occurs first (up to approximately 2 years)
measure: Overall Survival (OS)
timeFrame: : From Baseline to the time of death from any cause (up to approximately 2 years)
Other outcomes:
Locations:
city: Phoenix
country: United States
facility: Mayo Clinic Cancer Center
state: Arizona
city: Tampa
country: United States
facility: H. Lee Moffitt Cancer Center & Research Institute, Inc.
state: Florida
city: Baltimore
country: United States
facility: Johns Hopkins University School of Medicine
state: Maryland
city: Detroit
country: United States
facility: Karmanos Cancer Institute
state: Michigan
city: Saint Louis
country: United States
facility: Washington University School of Medicine in St. Louis
state: Missouri
city: New York
country: United States
facility: New York University Langone Medical Center - Perlmutter Cancer Center
state: New York
city: New York
country: United States
facility: Columbia University, Herbert Irving Comprehensive Cancer Center
state: New York
city: Chapel Hill
country: United States
facility: University of North Carolina School of Medicine
state: North Carolina
city: Pittsburgh
country: United States
facility: University of Pittsburgh Medical Center
state: Pennsylvania
city: Greenville
country: United States
facility: Greenville Memorial Hospital
state: South Carolina
city: Fairfax
country: United States
facility: Inova Melanoma and Skin Cancer Center
state: Virginia
Study officials:
affiliation: Inovio Pharmaceuticals
name: Jeffrey Skolnik, MD
role: STUDY_DIRECTOR
References: